Skip to main content
. Author manuscript; available in PMC: 2014 May 7.
Published in final edited form as: Chem Commun (Camb). 2013 May 7;49(35):3617–3630. doi: 10.1039/c3cc00177f

Figure 9.

Figure 9

Chemical structures (top) and biological activities (bottom) of the rhodium metalloinsertor [Rh(bpy)2(chrysi)]3+ (left), and the DNA alkylating agent MNNG (right) studied in our laboratory.49 MMR-proficient (green) and MMR-deficient (red) cells were treated with varying concentrations of each compound and the proliferation of growth was quantified via a BrdU incorporation assay. With the rhodium metalloinsertor, the MMR-deficient cells are preferentially targeted over MMR-proficient cells, whereas the DNA alkylating agent targets the MMR-proficient cells, a trend seen with many commonly used DNA-targeted therapeutics.